Fapon Biotech attaches great importance to independent R&D, making continuous breakthroughs and iteration. We have world-class R&D and application platforms, rich experiences in reagent material labeling, matching and screening, reagent development debugging and performance optimization, with an excellent technology development process implement to meet customer needs precisely.
Eukaryotic Recombinant Expression Platform
The platform covers a variety of technologies, such as cell fermentation, mammalian cell expression of recombinant antibodies/antigens, and protein analysis. Our industry-leading hybridoma cell fermentation technology utilizes the serum-free culture technology, optimizes the culture conditions for different strains through DOE, featuring high stability, high antibody purity, high consistency and no animal-related ethical issues.
Based on the mammalian cell expression system, Fapon produces recombinant antibodies/antigens by domesticating CHO cells through expression plasmid and selecting stable high-yield cell lines, which has become the key to the company's future layout. Antibodies produced by this technology can achieve genetic optimization and modification, higher expression level, larger batch, higher production stability, higher consistency, and higher purity. The activity, specificity and thermal stability of some products are better than those antibodies produced with traditional methods.
Antibodies produced by this technology platform not only has the advantages of conventional technologies but also avoids their disadvantages, enabling the production of monoclonal antibodies to be characterized by automatic operation, high-efficiency separation and purification, and economical procedures. Meanwhile, genetic recombination technology also allows our antibodies to meet the research needs of different disciplines and various market needs, representing the development direction of monoclonal antibodies in the future.